

## LÄHDEKIRJALLISUUS

- Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C ym. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. *Vet Pathol.* 2010;47:414-33.
- Valli VE, San Myint M, Barthel A, Bienzle D, Caswell J, Colbatzky F ym. Classification of canine malignant lymphomas according to the World Health Organization criteria. *Vet Pathol.* 2011;48:198-211.
- Vail D, Pinkerton M, Young K. Hematopoietic tumors. Kirjassa: Vail D, toim. Small animal clinical oncology, 5.painos. London, UK: Elsevier Health Sciences; 2013, 608-78.
- Cowell RL, Dorsey KE, Meinkoth JH. Lymph node cytology. *Vet Clin North Am Small Anim Pract.* 2003;33:47-67.
- Valli VE, Kass PH, San Myint M, Scott F. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. *Vet Pathol.* 2013;50:738-48.
- Marconato L, Aresu L, Stefanello D, Comazzi S, Martini V, Ferrari R ym. Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers. *J Immunother Cancer.* 2019;7:146,019-0624-y.
- Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J ym. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, 1997. *Histopathology* 2000;36:69-86.
- Comazzi S, Marelli S, Cozzi M, Rizzi R, Finotello R, Henriques J ym. Breed-associated risks for developing canine lymphoma differ among countries: an European canine lymphoma network study. *BMC Vet Res.* 2018;14:232,018-1557-2.
- Teske E, de Vos JP, Egberink HF, Vos JH. Clustering in canine malignant lymphoma. *Vet Q.* 1994;16:134-6.
- Gavazza A, Presciuttini S, Barale R, Lubas G, Gugliucci B. Association between canine malignant lymphoma, living in industrial areas, and use of chemicals by dog owners. *J Vet Intern Med.* 2001;15:190-5.
- Reif JS, Lower KS, Ogilvie GK. Residential exposure to magnetic fields and risk of canine lymphoma. *Am J Epidemiol.* 1995;141:352-9.
- Ghernati I, Auger C, Chabanne L, Corbin A, Bonnefont C, Magnol JP ym. Characterization of a canine long-term T cell line (DLC 01) established from a dog with Sezary syndrome and producing retroviral particles. *Leukemia* 1999;13:1281-90.
- Milman G, Smith KC, Erles K. Serological detection of Epstein-Barr virus infection in dogs and cats. *Vet Microbiol.* 2011;150:15-20.
- Zandvliet M, Teske E. Mechanisms of drug resistance in veterinary oncology - A review with an emphasis on canine lymphoma. *Vet Sci.* 2015;2:150-84.
- Aresu L, Martini V, Rossi F, Vignoli M, Sampaolo M, Arico A ym. Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation. *Vet Comp Oncol.* 2015;13:348-62.
- Risbon RE, de Lorimier LP, Skorupski K, Burgess KE, Bergman PJ, Carreras J ym. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004). *J Vet Intern Med.* 2006;20:1389-97.
- Regan RC, Kaplan MS, Bailey DB. Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: results of a survey of veterinarians. *Vet Comp Oncol.* 2013;11:287-95.
- Sapierzynski R, Dolka I, Fabisiak M. High agreement of routine cytopathology and immunocytochemistry in canine lymphomas. *Pol J Vet Sci.* 2012;15:247-52.
- Comazzi S, Guscetti F, Marconato L. First meeting of the European canine lymphoma group. Workshop: state of the art and comparative aspects in canine lymphoma. CH-Lugano, 2013. *Hematol Oncol.* 2014;32:68-71.
- Gelain ME, Mazzilli M, Riondato F, Marconato L, Comazzi S. Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry. *Vet Immunol Immunopathol.* 2008;121:179-88.
- Ehrhart EJ, Wong S, Richter K, Zismann V, Grimes C, Hendricks W ym. Polymerase chain reaction for antigen receptor rearrangement: Benchmarking performance of a lymphoid clonality assay in diverse canine sample types. *J Vet Intern Med.* 2019;33:1392-402.
- Owen L. TNM Classification of Tumours in Domestic Animals. 1980; Saatavissa: <https://apps.who.int/iris/handle/10665/68618>.
- Marconato L. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. *Vet J.* 2011;188:34-8.
- Marconato L, Polton GA, Sabattini S, Dacasto M, Garden OA, Grant I ym. Conformity and controversies in the diagnosis, staging and follow-up evaluation of canine nodal lymphoma: a systematic review of the last 15 years of published literature. *Vet Comp Oncol.* 2017;15:1029-40.
- Flory AB, Rassnick KM, Stokol T, Scrivani PV, Erb HN. Stage migration in dogs with lymphoma. *J Vet Intern Med.* 2007;21:1041-7.
- Rosenberg MP, Matus RE, Patnaik AK. Prognostic factors in dogs with lymphoma and associated hypercalcemia. *J Vet Intern Med.* 1991;5:268-71.
- Marconato L, Bonfanti U, Stefanello D, Lorenzo MR, Romanelli G, Comazzi S ym. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference? *Vet Comp Oncol.* 2008;6:80-9.
- Gramer I, Kessler M, Geyer J. Determination of MDR1 gene expression for prediction of chemotherapy tolerance and treatment outcome in dogs with lymphoma. *Vet Comp Oncol.* 2015;13:363-72.
- Ammersbach MA, Kruth SA, Sears W, Bienzle D. The effect of glucocorticoids on canine lymphocyte marker expression and apoptosis. *J Vet Intern Med.* 2006;20:1166-71.
- Marconato L, Stefanello D, Valenti P, Bonfanti U, Comazzi S, Roccabianca P ym. Predictors of long-term survival in dogs with high-grade multicentric lymphoma. *J Am Vet Med Assoc.* 2011;238:480-5.
- Zandvliet M, Rutteman GR, Teske E. Prednisolone inclusion in a first-line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results. *Vet J.* 2013;197:656-61.
- Gustafson D, Page R. Cancer chemotherapy. Kirjassa: Vail D, toim. Small animal clinical oncology, 5. painos. LonLontoo, UK: Elsevier Health Sciences; 2013, 157-79.
- MacEwen EG, Brown NO, Patnaik AK, Hayes AA, Passe S. Cyclic combination chemotherapy of canine lymphosarcoma. *J Am Vet Med Assoc.* 1981;178:1178-81.
- Burton JH, Garrett-Mayer E, Thamm DH. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. *Vet Comp Oncol.* 2013;11:306-15.
- Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. *J Vet Intern Med.* 2002;16:704-9.
- Moore AS, Cotter SM, Rand WM, Wood CA, Williams LE, London CA ym. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. *J Vet Intern Med.* 2001;15:348-54.
- Simon D, Nolte I, Eberle N, Abbrederis N, Killich M, Hirschberger J. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. *J Vet Intern Med.* 2006;20:948-54.
- Curran K, Thamm DH. Retrospective analysis for treatment of naive canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol. *Vet Comp Oncol.* 2016;14 Suppl 1:147-55.
- MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? *J Vet Intern Med.* 2005;19:732-6.
- Al-Nadaf S, Rebhun RB, Curran KM, Venable RO, Skorupski KA, Willcox JL ym. Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma. *BMC Vet Res.* 2018;14:356,018-1688-5.
- Elliott JW, Cripps P, Marrington AM, Grant IA, Blackwood L. Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma. *Vet Comp Oncol.* 2013;11:185-98.
- Marquardt TM, Lindley SES, Smith AN, Cannon CM, Rodriguez CO Jr, Thamm DH ym. Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma. *J Am Vet Med Assoc.* 2019;254:236-42.
- Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. *J Vet Intern Med.* 1993;7:289-95.
- Brown PM, Tzannes S, Nguyen S, White J, Langova V. LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma. *Vet Comp Oncol.* 2018;16:108-13.
- Elliott J, Baines S. A Retrospective study of multi-agent chemotherapy including either cyclophosphamide or lomustine as initial therapy for canine high-grade T-cell lymphoma (2011-2017). *Aust Vet J.* 2019;97:308-15.
- Smith AN, Klahn S, Phillips B, Parshley L, Bennett P, Flory A ym. ACVIM small animal consensus statement on safe use of cytotoxic chemotherapeutics in veterinary practice. *J Vet Intern Med.* 2018;32:904-13.
- Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. *Vet Comp Oncol.* 2016;14:417-46.
- Tomiya H, Takahashi M, Fujino Y, Ohno K, Tsujimoto H. Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol. *J Vet Med Sci.* 2010;72:1391-7.
- Gaeta R, Brown D, Cohen R, Sorenmo K. Risk factors for development of sterile haemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case-control study. *Vet Comp Oncol.* 2014;12:277-86.
- Hallman BE, Hauck ML, Williams LE, Hess PR, Suter SE. Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin. *J Vet Intern Med.* 2019;33:783-91.
- Marrington AM, Killick DR, Grant IA, Blackwood L. Toxicity associated with epirubicin treatments in a large case series of dogs. *Vet Comp Oncol.* 2012;10:113-23.
- Wang SL, Lee JJ, Liao AT. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. *Can Vet J.* 2016;57:271-6.
- Kristal O, Rassnick KM, Gliatto JM, Northrup NC, Chretien JD, Morrison-Collister K ym. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. *J Vet Intern Med.* 2004;18:75-80.
- Lisowska M, Pawlak A, Kutkowska J, Hildebrand W, Ugorski M, Rapak A ym. Development of novel monoclonal antibodies to dog leukocyte antigen DR displaying direct and immune-mediated cytotoxicity toward canine lymphoma cell lines. *Hematol Oncol.* 2018;36:554-60.

55. Beirao BC, Raposo T, Jain S, Hupp T, Argyle DJ. Challenges and opportunities for monoclonal antibody therapy in veterinary oncology. *Vet J.* 2016;218:40-50.
56. Marconato L, Frayssinet P, Rouquet N, Comazzi S, Leone VF, Laganga P ym. Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma. *Clin Cancer Res.* 2014;20:668-77.
57. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH ym. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. *PLoS One.* 2011;6:e24167.
58. Impellizzeri JA, Gavazza A, Greissworth E, Crispo A, Montella M, Ciliberto G ym. Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma. *J Transl Med.* 2018;16:349,018-1738-6.
59. Vail DM, Michels GM, Khanna C, Selting KA, London CA. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. *Vet Comp Oncol.* 2010;8:28-37.
60. Flory AB, Rassnick KM, Erb HN, Garrett LD, Northrup NC, Selting KA ym. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007). *J Am Vet Med Assoc.* 2011;238:501-6.
61. LeBlanc AK, Mauldin GE, Milner RJ, LaDue TA, Mauldin GN, Bartges JW. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. *Vet Comp Oncol.* 2006;4:21-32.
62. Tanis JB, Mason SL, Maddox TW, Blackwood L, Killick DR, Amores-Fuster I ym. Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas. *Vet Comp Oncol.* 2018;16:361-9.
63. Rassnick KM, Mauldin GE, Al-Sarraf R, Mauldin GN, Moore AS, Mooney SC. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). *J Vet Intern Med.* 2002;16:576-80.
64. Moore AS, London CA, Wood CA, Williams LE, Cotter SM, L'Heureux DA ym. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. *J Vet Intern Med.* 1999;13:395-8.
65. Parsons-Doherty M, Poirier VJ, Monteith G. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma. *Can Vet J.* 2014;55:175-80.
66. Saba CF, Vickery KR, Clifford CA, Burgess KE, Phillips B, Vail DM ym. Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. *Vet Comp Oncol.* 2018;16:E76-82.
67. Avery PR, Burton J, Bromberek JL, Seelig DM, Elmslie R, Correa S ym. Flow cytometric characterization and clinical outcome of CD4+ T-cell lymphoma in dogs: 67 cases. *J Vet Intern Med.* 2014;28:538-46.
68. Zandvliet M, Teske E, Schrickx JA, Mol JA. A longitudinal study of ABC transporter expression in canine multicentric lymphoma. *Vet J.* 2015;205:263-71.
69. Jagielski D, Lechowski R, Hoffmann-Jagielska M, Winiarczyk S. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). *J Vet Med A Physiol Pathol Clin Med.* 2002;49:419-24.
70. Vaughan A, Johnson JL, Williams LE. Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. *J Vet Intern Med.* 2007;21:1332-9.